 Avid Bioservices NASDAQ:CDMO reported Q3 results.Quarterly Results Earnings per share decreased 20 year over year to a loss of 0.06, which missed the estimate by 0.02. Revenue of 13,585,000 less by 1.42 year over year, which missed the estimate of 15,420,000.Outlook Q4 revenue expected to be between 55,000,000 and 59,000,000.How To Listen To The Conference Call Date: Mar 10, 2020 Time: 06:04 AM ETView more earnings on CDMO Webcast URL: 52-week high: 8.38 52-week low: 3.37 Price action over last quarter: Up 12.17Company Profile Avid Bioservices is a clinical-stage biopharmaceutical company focused on development and current Good Manufacturing Practices cGMP of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries.See more from Benzinga 146 Biotechnology Stocks Moving In Thursdays SessionC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 